| Host: | HEK293 cells |
| Note: | STRICTLY FOR FURTHER SCIENTIFIC RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Formulation: | Lyophilised from a 0.22 Mu m filtered solution of PBS, pH 7.4. or Supplied as a 0.22 Mu m filtered solution in PBS, pH 7.4. |
| Storage Instruction: | Store at-20°C for up to 1 year from the date of receipt, and avoid repeat freeze-thaw cycles. |
| Determination Method: | < 0.1 EU/Mu g of the protein by LAL method. |
| Immunoreactivity: | 1.Measured by its binding ability in a functional ELISA. Immobilized Recombinant Human ACE2 at 2 Mu g/mL (100 Mu L/well) can bind Recombinant SARS-CoV-2 Spike S1, the EC50 of SARS-COV-2 Spike S1 is 6.79 ng/mL.|2.Immobilized Human ACE2 on C |
| Immunogen Region: | Val11-Arg682 |
| Immunogen: | Recombinant SARS-CoV-2 (2019-nCoV) Spike S1 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Val11-Arg682) of SARS-COV-2 (2019-nCoV) Spike S1 (Accession #YP_009724390.1) fused with an Fc, 6×His tag |
| Immunogen Sequence: | VSSQCVNLTTRTQLPPAYTN SFTRGVYYPDKVFRSSVLHS TQDLFLPFFSNVTWFHAIHV SGTNGTKRFDNPVLPFNDGV YFASTEKSNIIRGWIFGTTL DSKTQSLLIVNNATNVVIKV CEFQFCNDPFLGVYYHKNNK SWMESEFRVYSSANNCTFEY VSQPFLMDLEGKQGNFKNLR EFVFKNIDGYFKIYSKHTPI NLVRDLPQGFSALEPLVDLP IGINITRFQTLLALHRSYL |
| Background | Recombinant SARS-CoV-2 (2019-nCoV) Spike S1 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Val11-Arg682) of SARS-COV-2 (2019-nCoV) Spike S1 (Accession #YP_009724390.1) fused with an Fc, 6×His tag at the C-terminus. |
Information sourced from Uniprot.org